Fig. 1: Screening and characterization of SARS-CoV-2 and SARS-CoV cross-reactive monoclonal antibodies.
From: Cross-neutralizing antibodies bind a SARS-CoV-2 cryptic site and resist circulating variants
a The immunization schemes of two different strategies: immunized with the SARS-CoV-2 spike protein alone (upper) or with a combination of the SARS-CoV-2 and SARS-CoV spike proteins and the MERS-CoV RBD (lower). b The number of lead antibodies with cross-activity in each round of screening. c Characterization of 5 and 10 monoclonal antibodies obtained by the first and second immunization strategies, respectively. The neutralizing titers (IC50) based on the vesicular stomatitis virus pseudotyping system (VSV NAT) and the lentiviral virus pseudotyping system (LV NAT) were tested. ND means not detected. Asterisks indicate the top three monoclonal antibodies with excellent cross-neutralizing potency.
